Patents by Inventor Beatriz Royo

Beatriz Royo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9023402
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: May 5, 2015
    Assignee: ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda.
    Inventors: Werner E. Haas, Carlos C. Romao, Beatriz Royo, Ana Cristina Fernandes, Isabel Goncalves
  • Publication number: 20110237546
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Application
    Filed: April 1, 2011
    Publication date: September 29, 2011
    Inventors: Werner Haas, Carlos Romao, Beatriz Royo, Ana C. Fernandes, Isabel Goncalves
  • Patent number: 7964220
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: June 21, 2011
    Assignee: ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda.
    Inventors: Werner E. Haas, Carlos C. Romao, Beatriz Royo, Ana Cristina Fernandes, Isabel Goncalves
  • Publication number: 20070207217
    Abstract: The present invention relates to molybdenum carbonyl complexes useful for inhibiting tumor necrosis factor (TNF) production and for treating inflammatory diseases.
    Type: Application
    Filed: December 20, 2006
    Publication date: September 6, 2007
    Applicant: Alfama - Investigacao e Desenvolvimento De Productos Farmaceuticos Lda
    Inventors: Werner Haas, Carlos Romao, Sandra Rodrigues, Joao Seixas, Ana Pina, Beatriz Royo, Ana Fernandes, Isabel Goncalves
  • Publication number: 20060233890
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Application
    Filed: June 14, 2006
    Publication date: October 19, 2006
    Applicant: Alfama - Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda
    Inventors: Werner Haas, Carlos Romao, Beatriz Royo, Ana Fernandes, Isabel Goncalves
  • Publication number: 20060148900
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Application
    Filed: November 29, 2005
    Publication date: July 6, 2006
    Applicant: Alfama - Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda
    Inventors: Werner Haas, Carlos Romao, Beatriz Royo, Ana Fernandes, Isabel Goncalves